Oncostatin M is overexpressed in skin squamous-cell carcinoma and promotes tumor progression
Metrics: PDF 1695 views | HTML 2426 views | ?
Marie Simonneau1, Eric Frouin1,2, Vincent Huguier1,2, Cynthia Jermidi1,2, Jean François Jégou1, Julie Godet2, Anne Barra1,2, Isabelle Paris1,2, Pierre Levillain2, Sevda Cordier-Dirikoc3, Nathalie Pedretti3, François Xavier Bernard1,3, Jean Claude Lecron1,2, Franck Morel1 and Laure Favot1
1LITEC, Université de Poitiers, Poitiers, France
2CHU de Poitiers, Poitiers, France
3Bioalternatives, Gençay, France
Laure Favot, email: [email protected]
Keywords: oncostatin M; cytokine; skin cancer; tumor microenvironment; immunotherapy
Received: July 27, 2018 Accepted: November 01, 2018 Published: November 23, 2018
Cutaneous squamous cell carcinoma (cSCC) is the second most common keratinocyte malignancy and accounts for 20% of skin cancer deaths. Cancer is closely related to inflammation, but the contribution of the tumor microenvironment to cSCC development is poorly understood. We previously showed that oncostatin M (OSM), a cytokine belonging to the IL-6 family, promotes normal keratinocyte proliferation and migration, skin inflammation, and epidermal hyperplasia, both in vitro and in vivo. Here, we show that OSM is overexpressed in human cSCC and is associated with type 1 immune polarization. In vitro, OSM induced STAT-3 and ERK signaling, modified the expression of genes involved in cytokine signaling, proliferation, inhibition of apoptosis, and immune responses, and promoted proliferation and migration of malignant keratinocyte PDVC57 cells. PDVC57 cells grafted in the skin of mice led to rapid cSCC development, associated with OSM expression by tumor-infiltrating neutrophils. Finally, the absence of OSM (OSM-KO mice) led to a 30% reduction of tumor size and reduced M2 polarization in the tumor microenvironment. Globally, these results support a pro-tumoral role of OSM in cSCC development and suggest that a new therapeutic approach targeting this cytokine could be considered.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.